Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients
Main finding · Lumbar spine BMD changeResult — go to the resultDifference in lumbar spine T-score 0.4 unitAuthors' conclusion
Our findings among a Chinese population indicate that elevated CTX levels, particularly exceeding 0.480 ng/ml, are notably associated with enhanced therapeutic efficacy of zoledronic acid in boosting lumbar spine BMD.
Study context
- Population
- Chinese patients with primary osteoporosis hospitalized at least twice and receiving annual zoledronic acid
- Participants
- 472 patients
- Exposure
- Higher vs lower baseline CTX levels before annual zoledronic acid
- Outcome
- Change in BMD after zoledronic acid treatment
Methodological detailsstratified by baseline CTX tertile groups, ANOVA, generalized estimating equations
- Stratified by baseline CTX tertile groups
- ANOVA
- Generalized estimating equations
Main finding
Lumbar spine BMD change
Difference in lumbar spine T-score
0.4 unit
As reported in the abstract
Observational data: associations, not effects.
Further findings
- No discernible relationship between baseline CTX levels and bone mineral density (BMD) changes in hip or femoral neck
Original publication
Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients. Osteoporos Int. Published 4 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →